1-4 of 4
Chris Sereduk
Close
Sort by
Journal Articles

RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2

Yuan Xiao Zhu, Hongwei Yin, Laura A. Bruins, Chang-Xin Shi, Patrick Jedlowski, Meraj Aziz, Chris Sereduk, Klaus Martin Kortuem, Jessica E. Schmidt, Mia Champion, Esteban Braggio, A. Keith Stewart
Journal: Blood
Blood (2015) 125 (3): 483–491.
https://doi.org/10.1182/blood-2014-05-577130
Published: 2015
Includes: Supplemental data
Journal Articles

A Synthetic Lethality Druggable Genome RNAi Screen Identifies Genes Mediating Sensitivity To Lenalidomide In Multiple Myeloma Including RSK2

Yuan Xiao Zhu, Ph.D., Laura Bruins, Chang-Xin Shi, Ph.D., Jessica Schmidt, Chris Sereduk, Mia Champion, Ph.D., Esteban Braggio, Ph.D., Holly Yin, Ph.D., A. Keith Stewart, MBChB
Journal: Blood
Blood (2013) 122 (21): 3084.
https://doi.org/10.1182/blood.V122.21.3084.3084
Published: 2013
Journal Articles

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

Yuan Xiao Zhu, Rodger Tiedemann, Chang-Xin Shi, Holly Yin, Jessica E. Schmidt, Laura A. Bruins, Jonathan J. Keats, Esteban Braggio, Chris Sereduk, Spyro Mousses, A. Keith Stewart
Journal: Blood
Blood (2011) 117 (14): 3847–3857.
https://doi.org/10.1182/blood-2010-08-304022
Published: 2011
Includes: Supplemental data
Journal Articles

RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.

Yuan Xiao Zhu, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Chang-Xin Shi, PhD, Jessica Schmidt, BS, Laura Bruins, Jonathan J Keats, PhD, Holly Yin, PhD, Chris Sereduk, Spyro Mousses, PhD, A. Keith Stewart, MBChB
Journal: Blood
Blood (2009) 114 (22): 602.
https://doi.org/10.1182/blood.V114.22.602.602
Published: 2009